Matthew Call
2023
In 2023, Matthew Call earned a total compensation of $2.8M as Chief Operating Officer at iTeos Therapeutics, a 2% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $209,396 |
|---|---|
| Option Awards | $1,664,000 |
| Salary | $472,850 |
| Stock Awards | $432,960 |
| Other | $23,968 |
| Total | $2,803,174 |
Call received $1.7M in option awards, accounting for 59% of the total pay in 2023.
Call also received $209.4K in non-equity incentive plan, $472.9K in salary, $433K in stock awards and $24K in other compensation.
Rankings
In 2023, Matthew Call's compensation ranked 310th out of 2,242 executives tracked by ExecPay. In other words, Call earned more than 86.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 310 out of 2,242 | 86th |
Division Manufacturing | 172 out of 1,220 | 86th |
Major group Chemicals And Allied Products | 116 out of 687 | 83rd |
Industry group Drugs | 114 out of 658 | 83rd |
Industry Biological Products, Except Diagnostic Substances | 37 out of 162 | 77th |
Source: SEC filing on April 25, 2024.
Call's colleagues
We found two more compensation records of executives who worked with Matthew Call at iTeos Therapeutics in 2023.